Incidence of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Compliance in Chinese Real Clinical Setting: A Cross-Sectional Multicenter Survey

Cong Xue
Sun Yat-sen University Cancer Center

Lu Li
Sun Yat-sen University Cancer Center

Qing Xia
Renji Hospital of Shanghai Jiaotong University

Xin An
Sun Yat-sen University Cancer Center

Haifeng Li
Sun Yat-sen University Cancer Center

Riqing Huang
Sun Yat-sen University Cancer Center

Mei Hou
West China Hospital of Sichuan University

Xianglin Yuan
Tongji Hospital

Xi Chen
900th Hospital of PLA

Yi Ba
Tianjin Medical University Cancer Institute & Hospital

Yiping Zhang
Zhejiang Cancer Hospital

Lingdi Zhao
Henan Cancer Hospital

Yuankai Shi
Cancer Hospital Chinese Academy of Medical Sciences

Xichun Hu
Fudan University Shanghai Cancer Center

Shune Yang
Tumor Hospital of Xinjiang
Research Article

Keywords: chemotherapy-induced nausea and vomiting (CINV), antiemetics, guideline compliance, real clinical setting

DOI: https://doi.org/10.21203/rs.3.rs-457938/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background This survey aims to investigate the incidence of chemotherapy-induced nausea and vomiting (CINV) in Chinese real clinical setting and evaluate the effect of guideline-consistent CINV prophylaxis (GCCP) and guideline-inconsistent CINV prophylaxis (GICP) on incidence of complete response (CR) of CINV.

Materials and Methods A cross-sectional nationwide multicenter study assessing the guideline consistency and CINV incidence of patients was conducted at a total of 32 large medical centers from 26 provinces across the west, east, northeast and middle part of China between April and May 2021.

Result Data for 2964 patients were analyzed. Patients treated with moderately emetogenic chemotherapy (MEC) were more prone to experience CINV during the acute phase compared to those receiving highly emetogenic chemotherapy (HEC); patients receiving low or minimally emetogenic chemotherapy (L/mEC) were least likely to experience CINV during the overall phase among the whole study population. The prevalence of GCCP was 29.2% in the whole study population, and 13.6%, 35.7% and 45.1% for the patients receiving HEC, MEC and L/mEC, respectively. For patients receiving HEC and MEC, GCCP increased incidence of CR during both delayed and overall phases. For those receiving L/mEC and GICP, incidence of CR was not higher than that of patients receiving L/mEC and GCCP.

Conclusion This study revealed Chinese CINV status, the prevalence of GCCP in the real clinical setting and the association between GCCP and CR rate for the first time. The findings indicate that prescribing antiemetics in compliance with guidelines for all patients receiving chemotherapy is strongly suggested.

Implications For Practice

The prevalence of GCCP in the real clinical setting was unknown in China, despite international antiemetic guidelines have been issued and regularly update. Findings in this study revealed that GCCP prevalence needs improvement and GCCP has a positive effect on the incidence of CR. Therefore, it is highly recommended that oncologists prescribe guideline-consistent antiemetics for cancer patients receiving chemotherapy in the real clinical setting.

Introduction

Chemotherapy-induced nausea and vomiting (CINV) is considered as a common, debilitating reaction to chemotherapeutic agents[1]. The incidence of CINV has been well controlled as the development of effective antiemetics[2]. Although effective antiemetics and consensus guidelines for CINV are available nowadays, CINV still deteriorate patients’ quality of life and in the worst case even lead to discontinuation of chemotherapy, compromised effectiveness of chemotherapy and more costs on outpatient visits and hospitalization[3].
According to international guideline, chemotherapy regimens are categorized into four classes based on the antiemetic with the highest emetogenicity in the regimen\cite{4}, which are highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC), low emetogenic chemotherapy (LEC), and minimally emetogenic chemotherapy, respectively. CINV could occur in a biphasic mode consisting of acute (≤24h from administration of chemotherapy, day 1) phase and delayed (>24h from administration of chemotherapy, days 2–5) phase. Previous studies reported that CINV was more prone to occur in the delayed phase as compared with the acute phase\cite{5}.

Guideline consistency in practice is variable across different countries. Studies conducted in the United states and Europe have reported the unsatisfactory incidence of guideline adherence which were 57.3% and 29 %, respectively, and the findings in these two studies indicated that compliance with antiemetic guidelines has a positive effect on control of CINV during the overall phase (acute phase plus delayed phase) for patients administered HEC or MEC\cite{6, 7}. Thus the primary objective of this survey was to analyze the impact of guideline-consistent CINV prophylaxis (GCCP) and guideline-inconsistent CINV prophylaxis (GICP) on incidence of complete response (CR) in China. Besides, a number of clinical trials reported that use of newly modern antiemetics could increase rate of complete response (CR), such as palonosetron (PALO) and aprepitant \cite{8, 9}. Considering few studies about the effectiveness of 5-hydroxytryptamine-3 receptor antagonist (5HT3-RA) or aprepitant in combined regimens in the real clinical setting, investigating their effectiveness in combined regimens in Chinese clinical practice was also conducted.

**Materials And Methods**

This was a cross-sectional nationwide multicenter survey conducted at 32 large medical centers including cancer centers and general hospitals from 26 provinces across the west, east, northeast and middle part of China between April and May 2021. To keep balance, the number of patients at each study site was requested to range from 30 to 120. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by Ethics Committee of Sun Yat-sen University Cancer Center. Informed consent was obtained from all subjects and all subjects are above 18, and the ethical approval was provided in supplement 2.

**Patients**

Patients who were ≥ 18 years old and had already received HEC, MEC, low or minimally emetogenic chemotherapy (L/mEC) were eligible for the study. Patients were excluded if they had been received opioids or other drugs that interfere with the metabolism of antiemetics during chemotherapy treatment, and those who cannot express objective discomfort, cannot take food because of digestive tract obstruction, with brain metastases and concurrent radiation therapy were also excluded.

**Questionnaire design and outcomes**

The questionnaire included six sections as follows: demographic information, patients’ recall about control of CINV after the most recent chemotherapy, antiemetic regimens, adverse effects of antiemetics,
treatment adherence and medical costs. Oncologists filled out the questionnaire via asking patients pre-designed questions (Questionnaire is presented in supplemental 1).

Analyzing the data from questionnaire led to following outcomes: demographics, use of antiemetic medications for CINV, incidence of CINV, the effect of GCCP and GICP on incidence of complete response (CR) and prognostic factors for the overall CR. CR referred to no vomiting and no rescue therapy. This study analyzed CR during the acute, delayed and overall phases, respectively. The Emetogenicity of chemotherapy regimen was categorized into four classes, and the definition of GCCP in this study was based on the NCCN Antiemesis Guidelines Version 1.2019 [4] (supplemental Table 1). In our study, LEC and minimally emetogenic chemotherapy were analyzed as a group named L/mEC. For patients receiving LEC, GCCP was defined as use of single agent as follows: dexamethasone, metoclopramide, prochlorperazine or 5HT3-RA; using more than one antiemetic for patients receiving LEC was regarded as GICP; for patients receiving minimally emetogenic chemotherapy, no routine prophylaxis was defined as GCCP.

**Statistical Analyses**

Demographics and clinical characteristics of patients were compared among HEC, MEC, L/mEC groups using Chi-square test for categorical variables and Kruskal-Wallis test for age; post-hoc analysis was used to compare difference in distribution for gender and use of antiemetic therapy. Chi-square test was used to compare the incidence of CR between GCCP and GICP. Prognostic factors for CR during the overall period were identified via univariate and multivariate logistic regression analysis. The independent factors included in the analysis are as follows: gender, age, number of prophylactic antiemetics, use of 5HT3-RA, emetogenic risk level of chemotherapy, use of aprepitant, history of anticipatory nausea and vomiting (ANV), education level, degree of knowing illness and guideline compliance [10–12]. Two-sided P values < 0.05 were accepted as statistically significant. STATA software, version 15.0 was used for all statistical analyses.

**Ethical Considerations**

This cross-sectional multicenter survey was initiated by the Clinical Chemotherapy Committee of Chinese Anti Cancer Association (CACA) and the contents of questionnaire enshrine ethical considerations, without any invasion of privacy. All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by Ethics Committee of Sun Yat-sen University Cancer Center. Informed consent was obtained from all subjects and all subjects are above 18, and the ethical approval was provided in supplement 2.

**Result**

**Patients**

Of 3000 patients enrolled, as data for chemotherapy regimen were missing for 36 patients, data for 2964 patients treated with HEC, MEC or L/mEC were analyzed. Table 1 summarizes the characteristics of the 2964 patients (1184 treated with HEC, 1037 treated with MEC and 743 treated with L/mEC; 1516 men and...
1448 women; 1514 and 1450 patients from cancer center and general hospital, respectively). The median ages in HEC, MEC and L/MEC were 56, 56 and 57 years old, respectively. The 3 groups (HEC, MEC, L/MEC) of patients shared an unsimilar distribution of gender, prevalence of antiemetic usage, degree of knowing illness and percentages of cancer type ($P < 0.01$). General hospital and cancer center showed a similar distribution among 3 groups ($P = 0.179$). Greater proportions of male patients were in HEC and MEC cohort compared with L/MEC cohort ($P < 0.001$). A lower usage rate of antiemetics in MEC and L/mEC compared to HEC cohort ($P < 0.001$).
|                                    | N = 2,964 | HEC (N = 1,184) (%) | MEC (N = 1,037) (%) | L/mEC (N = 743) (%) | p^a |
|------------------------------------|-----------|---------------------|---------------------|---------------------|-----|
| Age, years, median (IQR)           | 2,945     | 56 (47, 64) (n = 1,179) | 56 (49, 65) (n = 1,030) | 57 (49, 66) (n = 736) | 0.011 |
| Gender                             |           |                     |                     |                     | <0.001 |
| Male                               | 1,516     | 616 (52.0)          | 587 (56.6)          | 313 (42.1)          |     |
| Female                             | 1,448     | 568 (48.0)          | 450 (43.4)          | 430 (57.9)          |     |
| Type of hospital                   |           |                     |                     |                     | 0.179 |
| General hospital                   | 1,450     | 559 (47.2)          | 508 (49.0)          | 383 (51.5)          |     |
| Cancer center                      | 1,514     | 625 (52.8)          | 529 (51.0)          | 360 (48.5)          |     |
| Use of antiemetic therapy          |           |                     |                     |                     | < 0.001 |
| No                                 | 24        | 0 (0.0)             | 10 (1.0)            | 14 (1.9)            |     |
| Yes                                | 2,940     | 1184 (100.0)        | 1027 (99.0)         | 729 (98.1)          |     |
| ANV                                |           |                     |                     |                     | 0.138 |
| No                                 | 2,609     | 1,059 (89.4)        | 900 (86.8)          | 650 (87.5)          |     |
| Yes                                | 355       | 125 (10.6)          | 137 (13.2)          | 93 (12.5)           |     |
| Education                          |           |                     |                     |                     | 0.086 |
| Low                                | 2,241     | 906 (81.1)          | 764 (77.8)          | 571 (81.6)          |     |
| High                               | 558       | 211 (18.9)          | 218 (22.2)          | 129 (18.4)          |     |
| Degree of knowing illness          |           |                     |                     |                     | 0.003 |
| Not at all                         | 176       | 68 (5.8)            | 66 (6.5)            | 42 (5.8)            |     |
| A little                           | 1,740     | 733 (62.4)          | 615 (60.8)          | 392 (54.1)          |     |
| Completely known                   | 994       | 373 (31.8)          | 330 (32.6)          | 291 (40.1)          |     |

Values represent number (%) of patients unless otherwise noted.

^aChi-square test for categorical data and Kruskal-Wallis test for age (skewed distribution).

Abbreviation: HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; L/MEC, low/minimally emetogenic chemotherapy; IQR, Interquartile range; ANV, anticipatory nausea and vomiting.
| Type of cancer               | N = 2,964 | HEC (N = 1,184) (%) | MEC (N = 1,037) (%) | L/mEC (N = 743) (%) | ρ<sup>a</sup> |
|-----------------------------|-----------|---------------------|---------------------|---------------------|--------------|
| Lung cancer                 | 788       | 485(61.6)           | 90(11.4)            | 213(27)             | <0.001       |
| Breast cancer               | 525       | 230(43.8)           | 68(13.0)            | 227(43.2)           |              |
| Head and neck cancer        | 84        | 44(52.4)            | 26(30.9)            | 14(16.7)            |              |
| Digestive system cancer     | 994       | 89(9.0)             | 695(69.9)           | 210(21.1)           |              |
| Gynecological cancer        | 102       | 54(52.9)            | 33(32.4)            | 15(14.7)            |              |
| Hematological cancer        | 244       | 157(64.3)           | 69(28.3)            | 18(7.4)             |              |
| Urogenital cancer           | 80        | 48(60.0)            | 12(15.0)            | 20(25.0)            |              |
| Sarcoma                     | 19        | 15(78.9)            | 1(5.3)              | 3(15.8)             |              |
| Melanoma                    | 11        | 4(36.4)             | 4(36.4)             | 3(27.2)             |              |
| Others                      | 117       | 58(49.6)            | 39(33.3)            | 20(17.1)            |              |

Values represent number (%) of patients unless otherwise noted.

<sup>a</sup>Chi-square test for categorical data and Kruskal-Wallis test for age (skewed distribution).

Abbreviation: HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; L/MEC, low/minimally emetogenic chemotherapy; IQR, Interquartile range; ANV, anticipatory nausea and vomiting.

### Antiemetic treatment and CINV status in the real world

65.69% (1947/2964) were given a combined regimen while 33.50% (993/2964) were given a single agent. Among patients who received single agent, most of them (97.99%, 973/993) were prescribed 5HT3-RA. 5HT3-RA and corticosteroid was the most common prescribed regimen among combined regimens (41.50%, 808/1947) (supplemental Table 2). 5HT3-RA nearly became the basis of an antiemetic regimen as 2876 out of 2964 patients had 5HT3-RA in their prophylaxis antiemetic regimens. PALO was the most commonly prescribed 5HT3-RA (n = 1068;37.13%), followed by Tropisetron (n = 817;28.41%), and only 2.68% (n = 77) were administered Azasetron which was the least used 5HT3-RA.

CR outcomes of two specific antiemetic regimens for HEC and MEC were describes respectively in supplemental Table 3. The patients treated with HEC and aprepitant-containing triple antiemetics (5HT3-
RA + dexamethasone + aprepitant) had statistically higher CR rates compared with patients treated with dual antiemetics (5HT3-RA + dexamethasone) during the acute phase and overall phase; but for the patients treated with MEC, the CR rate had no significant difference between above-mentioned dual antiemetics and triple antiemetics. Among the patients after HEC and triple antiemetics(5HT3-RA + dexamethasone + aprepitant), the CR rates between patients treated with PALO and patients treated with 1st generation 5HT3-RA did not show a statistically significant difference. Regarding the patients after MEC treated with dual antiemetics (5HT3-RA + dexamethasone) or triple antiemetics (5HT3-RA + dexamethasone + aprepitant), the CR rate in patients prescribed PALO was not statistically different from that in patients prescribed 1st generation 5HT3-RA.

During overall, acute and delayed phases, patients were more likely to experience nausea compared with vomiting (Fig. 1). During the overall phase, 33.4% of the whole study population experienced nausea while 9.7% experienced vomiting; patients administered MEC were most likely to experience nausea (38.3%). Patients receiving MEC also had the highest incidence of nausea and vomiting in the acute phase (53.2% and 22.9%, respectively). In the delayed phase, the incidence of vomiting in patients receiving HEC was highest (19.6%) while the incidence of nausea in patients receiving MEC was higher than that in patients receiving HEC (47.9% vs 45.7%). The incidence of acute nausea in patients receiving MEC and L/mEC was higher than that of delayed nausea (MEC: 53.2% vs 47.9%; L/mEC: 41.3% vs 38%). The incidence of acute vomiting in patients receiving HEC was slightly higher than the incidence of delayed vomiting (20.7% vs 19.6%), and for patients receiving MEC and L/mEC, they were both more likely to vomit in the acute phase compared to the delayed phase (22.9% vs 17%, 18.4% vs 14.5%, respectively).

GCCP vs GICP
Between the patients treated in cancer center and those treated in general hospital, the guideline compliance showed no statistically significant difference (51.2% vs 48.8%, \( P = 0.95 \)). The prevalence of GCCP was 29.2% (866/2964) in the whole study population, and 13.6% (161/1184), 35.7% (370/1037) and 45.1% (335/743) for the patients receiving HEC, MEC and L/mEC, respectively. As shown in Fig. 2, for the whole study population, higher incidence of CR in patients treated with GCCP was observed during overall, acute and delayed phases (\( P = 0.023 \) for acute CR; \( P < 0.001 \) for both delayed and overall CR). GCCP could significantly increase the incidence of CR in the patients treated with HEC (\( P = 0.007 \) for the delayed CR; \( P < 0.001 \) for the acute and overall CR). Regarding the patients treated with MEC, the incidence of acute CR in patients receiving GCCP was not statistically higher than that in the patients receiving GICP (\( P = 0.311 \)), but CR rates were both statistically higher in the patients treated with GCCP than that in the patients treated with GICP for both delayed and overall phases (\( P = 0.042, P = 0.007 \), respectively). For the patients treated with L/mEC, no statistically significant difference in CR rates between GCCP and GICP was observed during the acute, delayed and overall phases.

**Univariate and Multivariate analysis of prognostic factors for overall CR**
Univariate and multivariate logistic regression analyses were performed to identify several statistically significant predictors for overall CR (Table 2). The univariate analysis showed that male sex, older age,
two antiemetics versus single antiemetic, three antiemetics versus single antiemetic, L/mEC versus HEC, treatment with aprepitant, without ANV and GCCP were all statistically significant prognostic factors for overall CR. The multivariate analysis revealed that male sex (odds ratio [OR] for female sex, 0.542; 95% confidence interval [CI] 0.453–0.649; P < 0.001), treatment with aprepitant (OR, 2.102; 95% CI, 1.086–4.065; P = 0.027) without ANV (OR for with ANV, 0.277; 95% CI, 0.217–0.353; P < 0.001), two antiemetics versus single antiemetic (OR, 1.273; 95% CI, 1.054–1.537; P = 0.012), L/mEC versus HEC (OR, 1.653; 95% CI, 1.309–2.087; P < 0.001) and GCCP (OR, 1.369; 95% CI, 1.084–1.729; P = 0.008) were statistically significant independent predictors for overall CR (P < 0.05).
Table 2
Univariate and multivariate logistic regression model for overall CR

| Factor                                      | Univariate analysis | Multivariate analysis |
|---------------------------------------------|---------------------|-----------------------|
|                                             | OR (95%CI)          | P         | OR (95%CI)          | P         |
| Gender: female vs. male                     | 0.537(0.456–0.631)  | < 0.001  | 0.541(0.452–0.648)  | < 0.001  |
| Age (continuous variable)                  | 1.016(1.010–1.023)  | < 0.001  | 1.007(1.000–1.015)  | 0.056    |
| Number of prophylactic antiemetics one      | Reference           |          |                      |          |
| Two                                         | 1.283(1.081–1.523)  | 0.004    | 1.305(1.080–1.578)  | 0.006    |
| Three                                       | 2.295(1.625–3.240)  | < 0.001  | 0.983(0.451–2.141)  | 0.965    |
| Four                                        | 1.158(0.698–1.920)  | 0.570    | 0.620(0.264–1.455)  | 0.272    |
| 5HT3-RA: Yes vs. No                         | 0.729(0.440–1.208)  | 0.219    | 0.732(0.388–1.378)  | 0.333    |
| Chemotherapy                                | Reference           |          |                      |          |
| HEC                                         |                     |          |                      |          |
| MEC                                         | 1.024(0.853–1.229)  | 0.802    | 1.085(0.880–1.339)  | 0.445    |
| L/mEC                                       | 1.259(1.024–1.549)  | 0.029    | 1.462(1.142–1.873)  | 0.003    |
| Aprepitant: Yes vs. No                      | 1.712(1.327–2.209)  | < 0.001  | 2.188(1.131–4.234)  | 0.020    |
| ANV: Yes vs. No                             | 0.292(0.233–0.367)  | < 0.001  | 0.275(0.216–0.351)  | < 0.001  |
| Education: High vs. low                     | 0.952(0.777–1.167)  | 0.637    | 1.037(0.826–1.301)  | 0.755    |

Abbreviation: CI, confidence interval; ANV, Anticipatory nausea and vomiting; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; L/MEC, low/minimally emetogenic chemotherapy; OR, odds ratio; GCCP, guideline-consistent CINV (chemotherapy induced nausea and vomiting) prophylaxis; GICP, guideline-inconsistent CINV chemotherapy induced nausea and vomiting prophylaxis.
|                                | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
| Degree of knowing illness      |                     |                       |
| Not at all Reference           |                     |                       |
| A little                        | 1.120 (0.797–1.575) | 0.514                 |
|                                | 0.957 (0.657–1.395) | 0.821                 |
| Completely known               | 1.013 (0.713–1.440) | 0.942                 |
|                                | 0.870 (0.588–1.287) | 0.485                 |
| GCCP vs. GICP                  | 1.472 (1.226–1.767) | < 0.001               |
|                                | 1.369 (1.084–1.729) | 0.008                 |

**Abbreviation:** CI, confidence interval; ANV, Anticipatory nausea and vomiting; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; L/MEC, low/minimally emetogenic chemotherapy; OR, odds ratio; GCCP, guideline-consistent CINV (chemotherapy induced nausea and vomiting) prophylaxis; GICP, guideline-inconsistent CINV chemotherapy induced nausea and vomiting prophylaxis.

**Discussion**

For the first time this study revealed Chinese CINV status, the prevalence of GCCP in the real clinical setting and the association between GCCP and CR rate. The findings in this study indicate that CR rate in the patients treated with GCCP beyond that seen with patients treated with GICP thus standardizing the use of antiemetics in real clinical setting is of great significance. The strengths of this study lie in many aspects. It consisted of a total of 32 large medical centers and 2964 patients from 26 provinces of China. Compared with the previous western studies[6, 7], the bigger sample size in this study provided a more robust evaluation of the benefits of GCCP. More notably, the incidence of CR after patients receiving L/mEC was compared between GCCP and GICP for the first time[13], as patients treated with L/mEC were not enrolled in previous western studies.

This study illustrated that current antiemetic regimens in compliance with NCCN guideline effectively control chemotherapy-induced emesis in patients receiving HEC and MEC. In an American study (INSPIRE), Gilmore et al. found, among patients treated with HEC, higher rate of no CINV in GCCP group compared with GICP group during both acute and delayed phases (49.2% vs 37.8%, P = 0.024)[7]. For the patients treated with MEC in this study, although the positive effect of GCCP on acute CR rate was not statistically significant, INSPIRE study reported that rate of no emesis in patients treated with MEC and GCCP was statistically higher than that in GICP group (91.6% vs 81.2%, P = 0.020) during the overall phase[7]. Aapro et al. in Pan European Emesis Registry (PEER) study indicated that in Europe, the incidence of CR in GCCP was significantly higher than it was in GICP during the acute, delayed phases and overall period (OR 1.43, P = 0.027)[6]. So findings in this study support prescribing antiemetics in compliance with guidelines in the real clinical setting for patients receiving HEC, MEC as GCCP could
significantly increase the incidence of CR for patients receiving HEC and MEC. Besides, for the patients receiving L/mEC, no significant difference in CR rate between GCCP and GICP was observed, indicating that excessive treatment (more than one antiemetic) for patients receiving LEC and prescribing antiemetics for patients receiving minimally emetogenic chemotherapy could not increase the incidence of CR.

In this study, only 13.6% of patients prescribed HEC and 35.7% of patients prescribed MEC complied the NCCN 2019 guidelines, respectively, which were comparable with the results reported in the conducted by Aapro et al. (11%, 39%, respectively). However, this was not a satisfactory result when compared with the GCCP prevalence in a Japanese study, in which Hirotoshi et al. reported 96% of patients receiving carboplatin-based chemotherapy (HEC and MEC were both included) were in compliance with the antiemesis guidelines based on JSCO 2010 guidelines[14]. Except the fact of using different guidelines, Japan enacted the first cancer control law in 2006, which confirmed that political policies could influence compliance with guidelines[14]. Economic burden is another notable issue. The cost-effectiveness of using aprepitant was reported quite good in Germany, the United States and the United Kingdom[15]. But it has not been involved into Chinese health insurance, which might be responsible for the insufficient use of aprepitant in patients receiving HEC (only 255 out of 1184 patients receiving HEC were administered aprepitant in this survey), hence improving health care policy might be a practical measure to increase guideline consistency and reduce the burden of CINV.

The incidence of nausea during overall, acute and delayed phases was more frequent than vomiting, which was consistent with previous studies[16, 17]. Ng, T. L et al. reported that patients ranked nausea more of a problem than vomiting[18]. The incidence of nausea during the overall phase was approximately 3.5-fold higher than that in the vomiting. This implies the control of nausea in real clinical setting was much worse compared to the control of vomiting. For the overall study population, data generated in this study found that the incidence of acute CINV was higher than the incidence of delayed CINV, unlike results reported by previous studies indicating that incidence of delayed CINV was higher[16, 20]. This might because those previous studies analyzed first cycle of chemotherapy among chemotherapy-naïve patients [21]. While our study, as a cross-sectional study, referred to patients’ most recent treatment cycle consisting of diverse chemotherapy regimens, confounding factors were inevitable. Vidall et al. found the same pattern of CINV incidence as our study which might because they also referred to patients’ most recent cycle of chemotherapy[22]. The consistency might imply the incidence of CINV in the acute phase was indeed higher compared with delayed phase in real clinical setting. Unexpectedly, higher percentage of patients receiving MEC experienced nausea compared to patients receiving HEC, although the prevalence of GCCP in MEC was higher than that in HEC. This could be attributed to the insufficient education and contacts between oncologists and patients receiving MEC, unlike the patients receiving HEC, who were more prone to be educated about the prophylaxis of CINV.

5HT3-RA was the basis of an antiemetic regimen as 97.03% of patients had 5HT3-RA in their prophylaxis antiemetic regimens. A phase III clinical study reported that among different types of 5HT3-RA, PALO as the most commonly prescribed, its complete response (CR) rates for CINV were significantly higher
compared with 1st generation 5HT3-RA in the delayed and overall phases[8]. Two large phase III trials involving patients treated with MEC showed higher rate of preventing vomiting with PALO than with ondansetron or dolasetron[23, 24]. But in our study, regarding MEC, among patients treated with guideline-consistent dual antiemetics (5HT3-RA + dexamethasone) or triple antiemetics (5HT3-RA + dexamethasone + aprepitant), PALO did not show a higher CR rate when compared with the 1st generation 5HT3-RA. The reason might because in previous clinical trials patients received single agent, while in our clinical setting, most patients received combined antiemetic regimens. Therefore, in terms of combined antiemetic regimens in the real clinical setting, selection between PALO and 1st generation 5HT3-RA needs further verification.

Regarding the patients receiving HEC, the addition of aprepitant into dual antiemetics is of great significance as triple antiemetics (5HT3-RA + dexamethasone + aprepitant) had higher CR rates in acute and overall phases compared with dual antiemetics (5HT3-RA + dexamethasone). This result was comparable with the study by Navari et al., in which they found addition of aprepitant to a standard regimen of 5HT3-RA and dexamethasone in patients receiving HEC improves the CR rate of acute CINV[9]. Two trials involving patients receiving HEC reported significantly higher efficacy in the control of emesis with the addition of aprepitant to ondansetron plus dexamethasone than with ondansetron plus dexamethasone alone[25, 26], therefore, the efficacy and effectiveness of aprepitant were both confirmed via previous RCTs and this cross-sectional study in the real clinical setting.

This study identified several independent predictors for overall CR in accordance with previous studies—male, use of aprepitant and no ANV (anticipatory nausea and vomiting). Besides, our results indicated that GCCP, use of aprepitant, two antiemetics (versus single agent) and L/mEC (versus HEC) were the protective factors for overall CR. Differing from the widely accepted view, this study did not identify older age as the protective factor [21]. The reason might be attributed to the median age in our study was 56 years old, which led to an age strata bias.

The main limitation of this study was the data collection was based on patients’ recall about the most recent treatment, which led to more missing records compared to the records from patients’ daily diary. Another limitation was the results in this study may not be generalized to suburban areas in China. So above-mentioned weakness could have introduced recall bias and selection bias. Besides, most patients participated in this study were not naïve to chemotherapy, as a result, there might be more confounding factors leading to CINV, such as prior experience of poorly controlled emesis, anxiety about chemotherapy. Despite above limitations, the results in this survey supported previous studies and further illustrated the positive effect of antiemetic guideline on controlling CINV.

**Conclusion**

This nationwide study reported Chinese CINV status, the prevalence of GCCP and the association between GCCP and CR rate in the real clinical setting for the first time. The findings in this study indicated that prevalence of GCCP still have much room for improvement and the incidence of CR in GCCP was
higher than that in GICP, thus it might be the best choice for patients to comply with GCCP in the real clinical setting. As such, prescribing antiemetics in compliance with guidelines for all patients receiving chemotherapy is strongly suggested.

Declarations

Ethics approval and consent to participate

All methods in this study were carried out in accordance with relevant guidelines and regulations. All experimental protocols were approved by Ethics Committee of Sun Yat-sen University Cancer Center. Informed consent was obtained from all subjects and all subjects are above 18, and the ethical approval was provided in supplement 2.

Consent for publication

All authors have approved the manuscript and agreed with publication.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors have no conflicts of interest to declare in this work.

Funding

This work was supported by the National Natural Science Foundation of China [81773279 to Dr. Yanxia Shi], Science and Technology Planning Project of Guangdong Province [2016A050502015, 2013B021800062 and 2012B061700082 to Dr. Yanxia Shi] and Young Teacher Foundation of Sun Yat-sen University [17ykzd33 to Dr. Yanxia Shi].

Authors’ contributions

Conception/design: Cong Xue, Lu Li, Qing Xia, Yanxia Shi, Wenqi Jiang, Jifeng Feng

Collection and/or assembly of data: Xin An, Haifeng Li, Riqing Huang, Mei Hou, Xianglin Yuan, Xi Chen, Yi Ba, Yiping Zhang, Lingdi Zhao, Yuankai Shi, Xichun Hu, Shune Yang, Jing Cheng, Yi Luo, Hui Liang, Qingfeng Zou, Zhengxiang Han, Kangsheng Gu, Zuoxing Niu, Yuhuan Gao, Li Xia, Runxiang Yang, Jianping Xiong, Qing Bu, Xiaodong Jiang, Xiaodong Xie, Tao Sun, Qingyuan Zhang, Shoucheng Ma, Shisheng Tan, Miao Li, Ningju Wang, Xiumei Wang

Data analysis and interpretation: Cong Xue, Lu Li, Qing Xia, Yanxia Shi
Acknowledgments

This work was supported by the National Natural Science Foundation of China [81773279 to Dr. Yanxia Shi], Science and Technology Planning Project of Guangdong Province [2016A050502015, 2013B021800062 and 2012B061700082 to Dr. Yanxia Shi] and Young Teacher Foundation of Sun Yat-sen University [17ykzd33 to Dr. Yanxia Shi]. We thank the Clinical Chemotherapy Committee of Chinese Anti Cancer Association (CACA) and the Chinese Journal of the Frontiers of Medical Science (Electronic Version) Editorial Department of People's Medical publishing house for initiating this survey. We also thank all study participants and investigators for their cooperation and participation.

References

1. Naito Y, Kai Y, Ishikawa T et al. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer 2020; 27: 122-128.

2. Navari RM, Longo DL, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. New England Journal of Medicine 2016; 374: 1356-1367.

3. Craver C, Gayle J, Balu S, Buchner D. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 2011; 14: 87-98.

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 1.2019[OL].(2019-02-28)[2019-8-30].
http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. In.

5. Fernandez-Ortega P, Caloto MT, Chirveches E et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer 2012; 20: 3141-3148.

6. Aapro M, Molassiotis A, Dicato M et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012; 23: 1986-1992.

7. Gilmore JW, Peacock NW, Gu A et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 2014; 10: 68-74.

8. Schwartzberg L, Barbour SY, Morrow GR et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 2014; 22: 469-477.

9. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting—two new agents. J Support Oncol 2003; 1: 89-103.
10. Molassiotis A, Aapro M, Dicato M et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 2014; 47: 839-848 e834.

11. Pirri C, Katris P, Trotter J et al. Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 2011; 19: 1549-1563.

12. du Bois A, Meerpohl HG, Vach W et al. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992; 28: 450-457.

13. Hayashi T, Shimokawa M, Matsu K et al. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study. Cancer Manag Res 2018; 10: 4249-4255.

14. Iihara H, Shimokawa M, Hayashi T et al. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. The Oncologist 2019; 25.

15. Yoshida I, Tamura K, Miyamoto T et al. Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan. In Vivo 2019; 33: 1355-1362.

16. Grunberg SM, Deuson RR, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100: 2261-2268.

17. Molassiotis A, Saunders MP, Valle J et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008; 16: 201-208.

18. Ng TL, Hutton B, Clemons M. Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist 2015; 20: 576-583.

19. Warr DG HP, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822–2830 [published correction appears in J Clin Oncol 2005;14:5851]. J Clin Oncol 2005; 23: 2822–2830.

20. Glaus A, Knipping C, Morant R et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004; 12: 708-715.

21. Natale JJ. Overview of the prevention and management of CINV. Am J Manag Care 2018; 24: S391-S397.

22. Vidall C, Fernandez-Ortega P, Cortinovis D et al. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey. Support Care Cancer 2015; 23: 3297-3305.

23. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
24. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.

25. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.

26. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.

Figures
Incidence of chemotherapy-induced nausea and vomiting among patients who received HEC (highly emetogenic chemotherapy), MEC (moderately emetogenic chemotherapy), L/mEC (low/minimally emetogenic chemotherapy) and all patients during acute, delayed and overall phases. (A): Incidence of nausea. (B): Incidence of vomiting. Abbreviation: All, the whole study population; HEC, highly emetogenic

Figure 1
chemotherapy; MEC, moderately emetogenic chemotherapy; L/MEC, low/minimally emetogenic chemotherapy.

Figure 2

Incidence of CR compared between GCCP and GICP during acute, delayed and overall phases after the most recent chemotherapy. (A): The graph shows the Incidence of overall CR between GCCP and GICP in patients receiving HEC, MEC and L/mEC, respectively, and in the whole study population. (B) The graph
shows the Incidence of acute CR between GCCP and GICP in patients receiving HEC, MEC and L/mEC, respectively, and in the whole study population. (C) The graph shows the Incidence of delayed CR between GCCP and GICP in patients receiving HEC, MEC and L/mEC, respectively, and in the whole study population. The data are presented as percentages and were tested using the chi-square test.

Abbreviation: : All, the whole study population; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; L/MEC, low/minimally emetogenic chemotherapy; GCCP, guideline-consistent CINV chemotherapy induced nausea and vomiting prophylaxis; GICP, guideline-inconsistent CINV chemotherapy induced nausea and vomiting prophylaxis (GCCP/GICP); CR, complete response.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaltables.docx